Induction of apoptosis in MCF-7: WS8 breast cancer cells by β-Lapachone

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1876-1885

  Wuerzberger, Shelly M ^a   Pink, John J ^a   Planchon, Sarah M ^a   Byers, Krista L ^a   Bornmann, William G ^b   Boothman, David A ^a,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA LAPACHONE; CAMPTOTHECIN; DNA TOPOISOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN MCF 7; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL CYCLE; CELL CYCLE PROTEINS; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LETHAL DOSE 50; NAPHTHOQUINONES; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE INHIBITORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032080821     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Cruz, F. S., Docampo, R., and de Souza, W. Effect of β-lapachone on hydrogen peroxide production in Trypanosoma cruzi. Acta Trop., 35: 35-40, 1978.
2. Docampo, R., Lopes, J. N., Cruz, F. S., and Souza, W. Trypanosoma cruzi: ultrastructural and metabolic alterations of epimastigotes by β-lapachone. Exp. Parasitol., 42: 142-149, 1977.
3. Schmidt, T. J., Miller-Diener, A., and Litwack, G. β-Lapachone, a specific competitive inhibitor of ligand binding to the glucocorticoid receptor. J. Biol. Chem., 259: 9536-9543, 1984.
4. Planchon, S. M., Wuerzberger, S. M., Frydman, B., Witiak, D. T., Hutson, P., Church, D. R., Wilding, G., and Boothman, D. A. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res., 55: 3706-3711, 1995.
5. Li, C. J., Wang, C., and Pardee, A. B. Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res., 55: 3712-3715, 1995.
6. Docampo, R., Cruz, F. S., Boveris, A., Muniz, R. P., and Esquivel, D. M. β-Lapachone enhancement of lipid peroxidation and superoxide anion and hydrogen peroxide formation by sarcoma 180 ascites tumor cells. Biochem. Pharmacol., 28: 723-728, 1979.
7. Boothman, D. A., Trask, D. K., and Pardee, A. B. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res., 49: 605-612, 1989.
8. Li, C. J., Averboukh, L., and Pardee, A. B. β-Lapachone, a novel topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem., 268: 22463-22468, 1993.
9. Boothman, D. A., and Pardee, A. B. Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc. Natl. Acad. Sci. USA, 86: 4963-4967, 1989.
10. Boothman, D. A., Greer, S., and Pardee, A. B. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res., 47: 5361-5366, 1987.
11. Boothman, D. A., Wang, M., Schea, R. A., Burrows, H. L., Strickfaden, S., and Owens, J. K. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys., 24: 939-948, 1992.
12. Frydman, B., Marton, L. J., Sun, J. S., Neder, K., Witiak, D. T., Liu, A. A., Wang, H., Mao, Y., Wu, H., Sanders, M. M., and Liu, L. F. Induction of DNA topoisomerase II-mediated DNA cleavage by β-lapachone and related naphthoquinones. Cancer Res., 57: 620-627, 1997.
13. James, C., Gschmeissner, S., Fraser, A., and Evan, G. I. CED-4 induces chromatin condensation in Schizosaccharomyces pombe and is inhibited by direct physical association with CED-9. Curr. Biol., 7: 246-252, 1997.
14. Sternglaz, R. DNA topoisomerases. Curr. Opin. Cell Biol., 1: 533-535, 1989.
15. Champoux, J. J. Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones. Nucleic Acids Res., 20: 3347-3352, 1992.
16. Hsiang, Y-H., Wu, H-Y., and Liu, L. F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res., 48: 3230-3235, 1985.
17. Husain, I., Mohler, J. L., Seigler, H. F., and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54: 539-546, 1994.
18. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
19. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
20. Shimada, Y., Rothenberg, M., Hilsenbeck, S. G., Burris, H. R., Degen, D., and Von, H. D. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs, 5: 202-206, 1994.
21. O'Reilly, S., Kennedy, M. J., Rowinsky, E. K., and Donehower, R. C. Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy. Breast Cancer Res. Treat., 33: 1-17, 1995.
22. Miller, A. A., Hargis, J. B., Lilenbaum, R. C., Fields, S. Z., Rosner, G. L., and Schilsky, R. L. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J. Clin. Oncol., 12: 2743-2750, 1994.
23. Musgrove, E. A., and Sutherland, R. L. Cell cycle control by steroid hormones. Semin. Cancer Biol., 5: 381-389, 1994.
24. Boothman, D. A., Fukunaga, N., and Wang, M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res., 54: 4618-4626, 1994.
25. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
26. 1 arrest after DNA damage. Environ. Health Perspect., 5: 55-58, 1993.
27. Hsiang, Y-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
28. Kastan, M. B. p53: a determinant of the cell cycle response to DNA damage. Adv. Exp. Med. Biol., 339: 291-293, 1993.
29. Meikrantz, W., Gisselbrecht, S., Tam, S. W., and Schlegel, R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3754-3758, 1994.
30. Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res., 55: 228-231, 1995.
31. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
32. Musgrove, E. A., Lee, C. S., Cornish, A. L., Swarbrick, A., and Sutherland, R. L. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol. Endocrinol., 11: 54-66, 1997.
33. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
34. Lane, D. P., Midgley, C. A., Hupp, T. R., Lu, X., Vojtesek, B., and Picksley, S. M. On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. Philos. Trans. R. Soc. Lond. B Biol. Sci. 347: 83-87, 1995.
35. Elbendary, A., Berchuck, A., Davis, P., Havrilesky, L., Bast, R. C., Jr., Iglehart, J. D., and Marks, J. R. Transforming growth factor β 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ., 5: 1301-1307, 1994.
36. El-Deiry, W. S., Tokino, T., Waldman, T., Oliner, J. D., Velculescu, V. E., Burrell, M., Hill, D. E., Healy, E., Rees, J. L., Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.
37. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin-induced apoptosis. Cancer Res., 53: 1853-1861, 1993.
38. Danks, M. K., Garrett, K. E., Marion, R. C., and Whipple, D. O. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res., 56: 1664-1673, 1996.
39. Casiano, C. A., Martin, S. J., Green, D. R., and Tan, E. M. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J. Exp. Med., 184: 765-770, 1996.
40. Goswami, P. C., Roti Roti, J. L., and Hunt, C. R. The cell cycle-coupled expression of topoisomerase IIα during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol. Cell. Biol., 16: 1500-1508, 1996.
41. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
42. An, B., Johnson, D. E., Jin, J., Antoku, K., and Dou, Q. P. Bcl-2-and CrmA-inhibitable dephosphorylation and cleavage of retinoblastoma protein during etoposide-induced apoptosis. Int. J. Mol. Med., 1: 131-136, 1998.
43. Oberhammer, F. A., Hochegger, K., Froschl, G., Tiefenbacher, R., and Pavelka, M. Chromatin condensation during apoptosis is accompanied by degradation of lamin A + B, without enhanced activation of cdc2 kinase. J. Cell Biol., 126: 827-837, 1994.
44. Pink, J., Wuerzberger, S. M., Srinivasan, A., Tomaselli, T., and Boothman, DA. Activation of Ced-3/ICE family proteases in human breast cancer cells undergoing apoptosis in response to topoisomerase I poisons. In: Programmed Cell Death Symposium, American Association for Cancer Research Mini-Symposium, October 19-23, 1996.
45. Wang, T. T., and Phang, J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55: 2487-2489, 1995.
46. Nurse, P. The Wellcome Lecture, 1992. Cell cycle control. Philos. Trans. R. Soc. Lond. B Biol. Sci., 341: 449-454, 1993.
47. Musgrove, E. A., Hamilton, J. A., Lee, C. S., Sweeney, K. J., Watts, C. K., and Sutherland, R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol., 13: 3577-3587, 1993.
48. Sutherland, R. L., Watts, C. K., and Musgrove, E. A. Cyclin gene expression and growth control in normal and neoplastic human breast epithelium. J. Steroid Biochem. Mol. Biol., 47: 99-106, 1993.
49. Sweeney, K. J., Musgrove, E. A., Watts, C. K., and Sutherland, R. L. Cyclins and breast cancer. Cancer Treat. Res., 83: 141-170, 1996.
50. Solary, E., Bertrand, R., and Pommier, Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk. Lymphoma, 15: 21-32, 1994.
51. Maity, A., McKenna, W. G., and Muschel, R. J. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother. Oncol., 31: 1-13, 1994.
52. 2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
53. Zhang, L. H., and Jenssen, D. Studies on intrachromosomal recombination in SP5/ V79 Chinese hamster cells upon exposure to different agents related to carcinogenesis. Carcinogenesis (Lond.), 15: 2303-2310, 1994.
54. Beidler, D. R., and Cheng, Y. C. Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol., 47: 907-914, 1995.
55. Pommier, Y., Leteurtre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.